UNSPSC 51292913: Opipramol

This classification denotes an anxiolytic and antidepressant agent with the molecular formula C23H29N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D23ZXO613C, chemically known as 2-naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (s)- but generally known as opipramol, which bears US NIH Compound Identifier 1302. European Medicines Agency schedules Opipramol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09450MIG. The term OPIPRAMOL is an International Non-Proprietary Name.

UNSPSC 51292913 Opipramol, a Commodity code, does not reflect the work actually being solicited under this classification in recent state and local procurement activity. The sole recent opportunity tagged to this code—Seminole County, Florida's IFB60459723LAS for naloxone and safe drug deactivation systems—involves procurement of opioid-reversal agents and drug-disposal equipment for community health support, not opipramol (an atypical antidepressant). The code appears to be a data-entry or classification error in the state and local procurement system, as opipramol is not a naloxone or drug-deactivation product.

Seminole County's IFB, posted June 30, 2026, with a response deadline of July 26, 2023, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year initial contract with one-year renewal option, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The county requires electronic bid submission through its e-Procurement Portal, compliance with E-Verify and drug-free workplace certifications, and specific insurance coverages including workers' compensation and general liability. The procurement carries potential FEMA funding and associated federal compliance obligations. No other recent state and local opportunities appear under this code, suggesting limited current activity and the classification mismatch.